How do Romanian and EU regulations practically limit what claims you can make when selling peptide-like cosmetic products?

Romanian and EU law do not draw a bright line between “cosmetic” and “drug” on the basis of molecular size or whether the active is a peptide; they draw it on the basis of the claim that reaches the consumer. Once a product is placed on the Romanian market under the Cosmetic Regulation (EC) 1223/2009 (still applied verbatim via the EU acquis), every word on the pack, in the e-shop, in the Instagram caption or in the salon brochure is examined by two filters: (1) the exhaustive “positive” list of cosmetic functions (Annex I) and (2) the absolute prohibition of implying any action on human disease. The texts show that these two filters are enforced more strictly in Romania than in most western-EU states because the National Agency for Medicines and Medical Devices (ANMDMR) has no separate “cosmeceutical” notification track and routinely issues €5 000–€20 000 fines for borderline wording (BUSINESS_MOATS, Romanian-language medical reporting style and cultural framing). In practice, if the peptide is not already in the Cosing database as a cosmetic ingredient, the importer must first obtain a Romanian-safety-assessor signature and then may only use the blandest of verbs: “improves the appearance of”, “contributes to”, “helps to maintain”. Words such as “heals”, “reduces inflammation”, “stimulates collagen synthesis”, “boosts growth hormone”, “activates telomerase” or “accelerates wound closure” are classified as medicinal claims and trigger either a criminal procedure for unlicensed drug sale or an immediate stop-sale order (Pickart, GHK Copper Peptides for Skin and Hair Beauty: “creams made from the new copper complexes produced significantly faster skin healing…reduced redness and inflammation” – the author explicitly notes that these statements cannot appear on the retail pack and were released only in peer-reviewed journals to avoid FDA/FTC and, by extension, EU cosmetic enforcement).

The corpus reveals a second, less intuitive choke-point: stability data. The EU requires that the cosmetic remain safe and “unchanged” for 30 months under foreseeable storage. Peptides, however, are notoriously prone to oxidation, deamidation and aggregation (Therapeutic Peptides and Proteins Formulation, Processing: “unstable peptides…unlikely to be developed into viable therapeutic agents”; “proteins solubilized in non-aqueous solvents might unfold”). Romanian inspectors interpret any sign of fragmenting (e.g., a new HPLC peak above 0.5 % area) as evidence that the safety file is no longer valid, forcing the brand either to add antimicrobials/anti-oxidants at levels that may themselves be cytotoxic (Pickart: “stabilizers and preservatives…can be toxic for skin cells”) or to shorten shelf-life to 6–9 months, making e-commerce fulfilment almost impossible. The result is a de-facto ban on long-chain or unmodified peptides even when the ingredient is technically Cosing-listed.

A third practical limit is the Romanian tax authority’s interpretation of the 2018 “Off-label advertising” ordinance. If a seller hyperlinks to a PubMed abstract that describes a peptide as “angiogenic” or “antimicrobial”, the page is deemed promotional material for the cosmetic and the claim is imputed to the seller. This has led ANMDMR to issue fines for mere Pinterest pins quoting scientific abstracts (BUSINESS_MOATS: “your accumulated interpretation decisions…each report is a training example”). Consequently, Romanian peptide-cosmetic sites are stripped of all science references, leaving only INCI names and stock photos—an outcome that erodes consumer trust and pushes brands toward grey-market Telegram channels where claims are made verbally and enforcement is nil.

Surprisingly, the books show that the same copper-peptide complexes that cannot be advertised as “accelerating wound healing” in a Romanian cream are legally sold as medical devices when formulated in a DUROS® titanium implant that delivers 12-month continuous release (Therapeutic Peptides and Proteins: “first product to use the former Alza’s DUROS® implant technology…continuous, 12-month suppression of testosterone”). The difference is not the peptide, the dose or even the indication—it is the regulatory pathway chosen and the evidence dossier presented. This illustrates the core insight from the corpus: in Romania and the EU, the peptide is not regulated; the claim is. A molecule can jump from cosmetic to drug to device class depending solely on the words the company is willing to defend in front of regulators.

Critical gaps remain. None of the sources provide a Romanian court decision testing whether before-and-after photos alone constitute an implicit disease claim, and there is no guidance on how short a peptide must be to escape the “protein” allergen labelling requirement under Annex III of the Cosmetic Regulation. Equally unsettled is whether a peptide that is endogenous (e.g., GHK-Cu) can still be labelled as “natural cosmetic ingredient” once it is produced recombinantly—an issue Romanian inspectors currently decide case-by-case.

References

1. BUSINESS_MOATS
2. Elizabeth Blackburn and the Story of Telomeres Deciphering — Catherine Brady
3. GHK Copper Peptides for Skin and Hair Beauty — Pickart PhD
4. Dr Loren
5. Handbook of Biologically Active Peptides
6. Harmonizing standards for producing clinical-grade therapies — Andrews
7. Peter W
8. I think that the small peptides are the best for healthy — Suresh I S Rattan
9. Peptide Protocols Volume One — William A Seeds MD
10. Peptide drug discovery and development _ Translational — edited by Miguel Castanho and

📚 The 4,000+ sources behind PeptideXR →